Infrared glucose sensor

• US 5,222,496 A
• Filed: 08/14/1992
• Issued: 06/29/1993
• Est. Priority Date: 02/02/1990
• Status: Expired due to Fees

• Current Assignee: Diabetes Control & Care Technology, Inc.
• Original Assignee: AngioMedics II Incorporated.
• Inventors: Wang, Qian, Clarke, Richard H.
• Primary Examiner(s): Howell, Kyle L.
• Assistant Examiner(s): NASSER, ROBERT L
• Application Number:
  US07/930,141
• Time in Patent Office: 319 Days
• Field of Search: 128/633-634, 128/664-666, 356/41
• US Class Current: 600/316
• CPC Class Codes: A61B 2562/0233 Special features of optical sensors or probes classified in A61B5/00
• CPC Class Codes: A61B 2562/043 in a linear array
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/1455 using optical sensors, e.g. spectral photometrical oximeters
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence

Abstract

Systems and methods for non-invasive blood analysis for the presence of glucose are disclosed in which blood is illuminated at a plurality of discrete wavelengths selected from the near infrared spectrum. Measurements of the intensity of transmitted or reflected light at such wavelengths are taken, and an analysis of transmittance or reflectance ratios for various wavelengths is performed. Changes in the ratios can be correlated with specific near infrared (IR) absorption peak for glucose at about 1600 nm +/-15 nm which varies with concentration of the analyte (the data wavelength) and the a second (reference) wavelength being sufficiently removed from the first so that measurements of light absorption at this second wavelength are relatively insensitive to the concentration of the analyte and yet the second wavelength is sufficiently close to the first wavelength to minimize interference from scattering effects and the like. Typically, the window bracketing these closely spaced wavelengths will be less than about 300 nm and preferably less than about 60 nm wide and, in some instances, more preferably less than about 30 nm wide.

Claims

1. A blood-glucose detection apparatus comprising:

infrared illumination means for non-invasively illuminating an in vivo blood sample in a patient at least two wavelengths in the near infrared spectrum;

detector means for non-invasively measuring light absorbed by said sample at least a first glucose data wavelength about 1600 nm and a second reference wavelength, and for converting said detected light into electrical signals, said signals being indicative of the intensity of said detected light at each wavelength;

the detector means further characterized as measuring light absorption at two closely-spaced wavelengths said first and second wavelengths separated by less than about 60 nanometers in order to minimize inference from extraneous factors.

2. The apparatus of claim 1 wherein the illumination means is broadband infrared emitter.

3. The apparatus of claim 1 wherein the illumination means comprises a plurality of discrete IR radiation sources emitting light at different wavelengths in the near infrared spectrum.

4. The apparatus of claim 1 wherein the illumination means emits at least two wavelengths of infrared radiation within a spectrum ranging from about 1000 to about 2500 nm.

5. The apparatus of claim 1 wherein the illumination means emits at least two wavelengths of infrared radiation within a spectrum ranging from about 1300 to about 2300 nm.

6. The apparatus of claim 1 wherein the illumination means emits at least two wavelengths of infrared radiation within a spectrum ranging from about 1500 to about 1800 nm.

7. The apparatus of claim 1 wherein said detector means detects the reflectance of said light upon said sample.

8. The apparatus of claim 1 wherein said detector means detects the transmittance of said light by said sample.

9. The apparatus of claim 1 wherein the detector further comprises a plurality of wavelength specific filters.

10. The apparatus of claim 1 wherein said first and second wavelengths are separated by less than about 30 nm.

11. The apparatus of claim 1 wherein one of said wavelengths is about 1600 nm for generating an analyte data signal and another of said wavelengths is about 1630-1660 for generation of a reference signal.

12. The apparatus of claim 1 wherein one of said wavelengths is about 1300 nm for generating a reference signal.

13. The apparatus of claim 1 wherein the apparatus further comprises an analyzing means for receiving and comparing said electrical signals to derive a detection ratio for at least two of said wavelengths, such that said ratio can be compared with predetermined values associated with known blood-analyte concentrations so as to detect the analyte level in said sample.

14. A method for detecting glucose in a blood sample, comprising the steps of:

illuminating a source of blood non-invasively through the tissue of a subject at a plurality of wavelengths within a narrow window selected in the near infrared spectrum;

detecting light effected by said blood and converting said detected light into electrical signals indicative of the intensity of said effected light at a plurality of wavelengths selected from the near infrared spectrum, including a first data wavelength and a second reference wavelength separated by less than about 60 nanometers;

analyzing said electrical signals to derive a ratio for at least two of said wavelengths; and

comparing said ratio to a predetermined value to detect the presence of an analyte in said blood.

15. The method of claim 14 wherein the step of detecting light effected by the blood further comprises measuring the intensity of the effected light at a first wavelength of about 1600 nm and a second closely-spaced wavelength separated from the first wavelength by less than about 60 nm.

16. The method of claim 15 wherein said first and second wavelengths are separated by less than about 30 nm.

17. The method of claim 14 wherein said detected light is a measure of the reflectance of said blood.

18. The method of claim 14 wherein said detected light is a measure of the transmittance of said blood.

19. The method of claim 14 wherein said tissue is skin.

20. The method of claim 14 wherein said tissue is in a nailbed.

21. The method of claim 14 wherein said tissue includes a vein.